<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJOG</journal-id><journal-title-group><journal-title>Open Journal of Obstetrics and Gynecology</journal-title></journal-title-group><issn pub-type="epub">2160-8792</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojog.2024.141016</article-id><article-id pub-id-type="publisher-id">OJOG-130949</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Evaluation of Spontaneous Fertility after Medical Treatment of Tubal Ectopic Pregnancy in Two Hospitals in the City of Yaounde
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Noa</surname><given-names>Ndoua Claude Cyrille</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tchedele</surname><given-names>Guidebta Hilary</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nyada</surname><given-names>Serge Robert</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Astrid</surname><given-names>Ruth Ndolo Kondo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ayissi</surname><given-names>Gregory</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ngo</surname><given-names>Dingom Anne Madye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tompeen</surname><given-names>Isidore</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Faculty of Medicine and Pharmaceutical sciences of the University of Douala, Douala, Cameroon</addr-line></aff><aff id="aff1"><addr-line>Faculty of Medicine and Biomedical Sciences of the University of Yaoundé I, Yaounde, Cameroon</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>01</month><year>2024</year></pub-date><volume>14</volume><issue>01</issue><fpage>175</fpage><lpage>185</lpage><history><date date-type="received"><day>11,</day>	<month>December</month>	<year>2023</year></date><date date-type="rev-recd"><day>28,</day>	<month>January</month>	<year>2024</year>	</date><date date-type="accepted"><day>31,</day>	<month>January</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: 
  Ectopic pregnancy is a major cause of maternal morbidity and mortality, estimated to occur in 1
  % 
  -
   
  2% of pregnancies worldwide. This condition also has an adverse effect on the fertility prospects of women who experience it. <b>Objective: </b>To determine the outcomes of subsequent spontaneous fertility after medical treatment of patients with methotrexate (MTX) in patients with ectopic pregnancy at two university teaching hospitals of Yaounde. <b>Methodology: </b>We carried out a cross-sectional study with retrospective data collection in two university teaching hospitals of Yaounde during 
  a six years period from 1<sup>st</sup> January 2015 to 31<sup>st</sup> May 2021. Seventy records of patients who had medical treatment for ectopic pregnancy were included in this study. Statistical analysis was performed using SPSS. 23. 
  The Chi-2 statistical test was used to compare qualitative variables. Binary logistic regression method was performed to identify independent risk factors associated with infertility after medical treatment of tubal ectopic pregnancy (TEP). The significance level was set at 0.05. <b>Results: </b>The mean age in our study population was 27.8 &#177; 3.8 years. According to the past medical history, 52.9% had a pelvic inflammatory disease (PID) and the most frequently germ found was C. trachomatis (47.1%). Almost 15% of our study population had previous surgery for EP. The median Fernandez score was 11 with a minimum score of 4 and a maximum score of 13. The route of administration of methotrexate was intramuscular in all our patients, and the single-dose protocol was used most frequently (58.6%). After medical treatment of the EP, we found a spontaneous conception rate of 58.6%. After multivariate analysis, we were unable to confirm that there was an association between a history of sexually transmitted infections (STIs) and fertility prognosis. <b>Conclusion: </b>The spontaneous fertility rate after medical management of EP was 58.6%, of which 73.2% were term pregnancies and 14.6% were recurrent ectopic pregnancies.
 
</p></abstract><kwd-group><kwd>Ectopic Pregnancy</kwd><kwd> Maternal Morbidity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Ectopic pregnancy, an important cause of maternal morbidity and mortality, is estimated to occur in approximately 1% - 2% of pregnancies worldwide [<xref ref-type="bibr" rid="scirp.130949-ref1">1</xref>] . Tubal localization accounts for 95% - 99% of ectopic pregnancies. Other localizations such as ovarian, cervical, cornual, and abdominal implants are rarely seen [<xref ref-type="bibr" rid="scirp.130949-ref2">2</xref>] . Chlamydia trachomatis infection of the genital tract, the most common sexually transmitted infection with a worldwide distribution, plays a key role in the occurrence of this localization [<xref ref-type="bibr" rid="scirp.130949-ref3">3</xref>] . Indeed, tubal infection by C. trachomatis, damages ciliated epithelium leading to the formation of intraluminal adhesions that predispose to entrapment of the zygote and the resultant ectopic implantation of the blastocyst.</p><p>Over the last 20 years, considerable progress has been made in the management of ectopic pregnancy. Conservative laparoscopic surgery is currently the cornerstone of treatment for tubal pregnancies in women who desire future fertility, while treatment with systemic methotrexate may, however, offer better prospects for fertility by avoiding surgical trauma to the tube. So what about reproductive outcomes for patients with EP? Clarifying the impact of each treatment modality on natural pregnancy outcomes to help tubal EP patients with fertility needs choose appropriate treatment. Hao et al. found that there was a significant difference in the chances of subsequent intrauterine pregnancy in tubal EP patients treated with MTX compared with those treated with surgery [odds ratios (OR) = 1.52, 95% confidence interval (CI): 1.20 - 1.92] [<xref ref-type="bibr" rid="scirp.130949-ref4">4</xref>] .</p><p>Several studies had evaluated fertility outcomes subsequent to medical and surgical treatment for ectopic pregnancy patients, with a cumulative incidence of intra uterine pregnancy up to 60% [<xref ref-type="bibr" rid="scirp.130949-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref4">4</xref>] , but none in our settings evaluates outcomes of fertility after medical treatment [<xref ref-type="bibr" rid="scirp.130949-ref5">5</xref>] . We therefore sought to determine the outcomes of subsequent spontaneous fertility after medical treatment of patients with MTX in patients with ectopic pregnancy at two university hospitals in the city of Yaounde.</p></sec><sec id="s2"><title>2. Methodology</title><sec id="s2_1"><title>2.1. Type of Study</title><p>We conducted an analytical cross-sectional study with retrospective data collection.</p></sec><sec id="s2_2"><title>2.2. Study Site</title><p>The study took place in maternity wards of university teaching hospitals in Yaounde: the Yaounde Central Hospital (YCH), the Yaounde Gyneco-Obstetrics and Pediatrics Hospital (YGOPH).</p></sec><sec id="s2_3"><title>2.3. Period/Duration of the Study</title><p>The study covered a period of 06 years five months, from 1<sup>st</sup> January 2015 to 31<sup>st</sup> May 2021. The duration of the study was seven months from 1<sup>st</sup> November 2023 to 1<sup>st</sup> May 2023.</p></sec><sec id="s2_4"><title>2.4. Study Population</title><p>1) Target population</p><p>Records of patients who had medical treatment for ectopic pregnancy in the study sites during study period.</p><p>2) Source population</p><p>Records of women of childbearing age diagnosed and treated for EP in the study sites during study period.</p><p>3) Sampling</p><p>The sampling was consecutive and exhaustive. Seventy patients (70) were recruited during the study period.</p><p>a) Inclusion criteria</p><p>We included all records of women diagnosed and treated medically with success for tubal ectopic pregnancy, who had conceived or not within two years of treatment and who had given their consent for the study.</p><p>b) Non-inclusion criteria</p><p>Records of women diagnosed and treated medically with success for tubal ectopic pregnancy with contraception.</p><p>c) Exclusion criteria</p><p>Records of patients who had undergone assisted reproductive technologies (ART), and patients whose records could not be analyzed were excluded from our study.</p></sec><sec id="s2_5"><title>2.5. Procedure and Ethical Considerations</title><p>After obtaining ethical approval and authorization for the research from the ethics committee of the Faculty of Medicine and Biomedical Sciences at the University of Yaound&#233; I and from hospital managers, patient records were selected from hospital registers. A pre-tested survey form was used to record sociodemographic and clinical characteristics and the treatment protocol used. By telephone interview, we presented the study to the patients, obtained their verbal consent and completed the missing information, in particular the notion of spontaneous conception or not, and the average time to conception after medical treatment.</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>Data were entered and analyzed using CSPro7.1 and SPSS 23.0. Tables were prepared using Microsoft Office Excel and Word 2013. The mean, standard deviation and median were calculated for quantitative variables, and the frequency, number of participants for qualitative variables. The Chi-2 statistical test was used to compare qualitative variables. The significance level was set at 5%, or 0.05.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Sociodemographic Characteristics</title><p><xref ref-type="table" rid="table1">Table 1</xref> shows the distribution of patients according to socio-demographic data. In our study, the most common age range was [21 - 35] years (95.7%); 31 patients (44.3%) were single; 55.7% had a university education and 34.3% (24 patients) were still at school. The mean age in our study population was 27.8 &#177; 3.81, with extremes ranging from 20 to 37 years.</p></sec><sec id="s3_2"><title>3.2. Past Medical History</title><p><xref ref-type="table" rid="table2">Table 2</xref> shows the distribution according to history of EP. 37 patients (52.9%) had a pelvic inflammatory disease and the most frequent germ found was Chlamydia trachomatis (47.1%); 10% of patients had a history of tubal obstruction; 10 patients (14.3%) had already undergone surgery for EP.</p></sec><sec id="s3_3"><title>3.3. Characteristics of EP</title><p>The median gestational age of EPs was 6 weeks’ amenorrhea, with extremes ranging from 4 weeks’ to 12 weeks’ amenorrhea; the most affected tube was the</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to age, marital status and study level</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Size (N = 70)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Age (years)</td></tr><tr><td align="center" valign="middle" >[16 - 20]</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.9</td></tr><tr><td align="center" valign="middle" >[21 - 35]</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >95.7</td></tr><tr><td align="center" valign="middle" >[36 - 40]</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[&gt;40]</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="3"  >Marital status</td></tr><tr><td align="center" valign="middle" >Single</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >44.3</td></tr><tr><td align="center" valign="middle" >Cohabiting</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >18.6</td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >37.1</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Niveau d’&#233;tude</td></tr><tr><td align="center" valign="middle" >None</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.9</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >41.4</td></tr><tr><td align="center" valign="middle" >Higher</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >55.7</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to risk factors for EP</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Size (N = 70)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >History of tubal obstruction</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >10.0</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >90.0</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Gynecological congenital malformation</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle"  colspan="3"  >History of STIs</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >61.4</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >38.6</td></tr><tr><td align="center" valign="middle"  colspan="3"  >C. Trachomatis infection</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >47.1</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >59.9</td></tr><tr><td align="center" valign="middle"  colspan="3"  >History of pelvic surgery</td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >14.3</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >85.7</td></tr></tbody></table></table-wrap><p>right tube in 51.4% and the most affected tubal segment was the ampulla in 61.4%; the median Fernandez score was 11 with a minimum score of 4 and a maximum score of 13 (<xref ref-type="table" rid="table3">Table 3</xref>).</p></sec><sec id="s3_4"><title>3.4. Medical Therapeutic Protocol</title><p>The administration route of methotrexate was intramuscular in all our patients, and the single-dose protocol was used most frequently (58.6%). The initial B-HCG level was &lt;3000 IU in 75.7% of cases and at Day 7, this level was less than 1000 IU in 51.4% of cases; the percentage of BHCG reduction during the first week ranged from 40% to 70% (<xref ref-type="table" rid="table4">Table 4</xref>).</p></sec><sec id="s3_5"><title>3.5. Spontaneous Conception after Medical Treatment of EP</title><p>After medical treatment of the EP we had a spontaneous conception rate of 58.6% (<xref ref-type="table" rid="table5">Table 5</xref>).</p></sec><sec id="s3_6"><title>3.6. Factors Associated with the Absence of Spontaneous Conception</title><p>The median time to conception after medical treatment of EP was 14 months, with a minimum of 4 months and a maximum of 36 months; 30 pregnancies (73.2%) were carried to term, and vaginal delivery was the preferred mode of delivery (73.6%) (<xref ref-type="table" rid="table6">Table 6</xref>).</p><sec id="s3_6_1"><title>3.6.1. Univariate Analysis</title><p><xref ref-type="table" rid="table7">Table 7</xref> shows that women with a history of STI had 3 times the risk of</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution according to gestational age, location and Fernandez score</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Size (N)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Gestational age (SA)</td></tr><tr><td align="center" valign="middle" >[&lt;6]</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >37.1</td></tr><tr><td align="center" valign="middle" >[6 - 8]</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >50</td></tr><tr><td align="center" valign="middle" >[&gt;8]</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >12.9</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Side</td></tr><tr><td align="center" valign="middle" >Left</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >48.6</td></tr><tr><td align="center" valign="middle" >Right</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >51.4</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Location</td></tr><tr><td align="center" valign="middle" >Ampullary</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >61.4</td></tr><tr><td align="center" valign="middle" >Infundibular</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >18.6</td></tr><tr><td align="center" valign="middle" >Isthmic</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >17.1</td></tr><tr><td align="center" valign="middle" >Interstitial</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.9</td></tr><tr><td align="center" valign="middle" >Fernandez score</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >[6 - 7]</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >[7 - 12]</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >94.3</td></tr><tr><td align="center" valign="middle" >[13 - 18]</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.7</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution according to methotrexate protocol and B-HCG kinetics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Size (N)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Route of administration</td></tr><tr><td align="center" valign="middle" >In-situ</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Intramuscular</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >100</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Method of administration</td></tr><tr><td align="center" valign="middle" >Single dose</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >58.6</td></tr><tr><td align="center" valign="middle" >Multidose</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >41.4</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Initial B-HCG</td></tr><tr><td align="center" valign="middle" >[&gt;5000]</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >18.6</td></tr><tr><td align="center" valign="middle" >[3000 - 5000]</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.7</td></tr><tr><td align="center" valign="middle" >[&lt;3000]</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >75.7</td></tr><tr><td align="center" valign="middle"  colspan="3"  >B-HCG at D7</td></tr><tr><td align="center" valign="middle" >[&gt;4000]</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.4</td></tr><tr><td align="center" valign="middle" >[1000 - 4000]</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >34.5</td></tr><tr><td align="center" valign="middle" >[&lt;1000]</td><td align="center" valign="middle" >36</td><td align="center" valign="middle" >51.4</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Percentage reduction in B-HCG after 1 week (%)</td></tr><tr><td align="center" valign="middle" >[&lt;40]</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >22.4</td></tr><tr><td align="center" valign="middle" >[40 - 70]</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >43.1</td></tr><tr><td align="center" valign="middle" >[&gt;70]</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >29.3</td></tr><tr><td align="center" valign="middle" >No reduction or increased</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >5.2</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution according to spontaneous conception after medical treatment of EP</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Size (N)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Spontaneous Yes conception</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >58.6</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >41.4</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Average time to conception and other reproductive outcomes after medical treatment of EP</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >Effectif (N)</th><th align="center" valign="middle" >Pourcentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="3"  >Time to conception after treatment (months)</td></tr><tr><td align="center" valign="middle" >[&lt;12]</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >17.1</td></tr><tr><td align="center" valign="middle" >[12 - 18]</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >63.4</td></tr><tr><td align="center" valign="middle" >[&gt;18]</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >19.5</td></tr><tr><td align="center" valign="middle"  colspan="3"  >Issue de la grossesse</td></tr><tr><td align="center" valign="middle" >Recurrence of EP</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >14.6</td></tr><tr><td align="center" valign="middle" >Miscarriage</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >12.2</td></tr><tr><td align="center" valign="middle" >Premature delivery</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Delivery at term</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >73.2</td></tr><tr><td align="center" valign="middle" >Mode of delivery</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Vaginal delivery</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >73.6</td></tr><tr><td align="center" valign="middle" >Cesaerian section</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >26.7</td></tr></tbody></table></table-wrap><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Factors associated with the absence of spontaneous conception after univariate analysis</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Variables</th><th align="center" valign="middle"  colspan="2"  >Absence of spontaneous conception</th><th align="center" valign="middle"  rowspan="2"  >OR (IC &#224; 95%)</th><th align="center" valign="middle"  rowspan="2"  >p</th></tr></thead><tr><td align="center" valign="middle" >N = 29; n(%)</td><td align="center" valign="middle" >N = 41; n(%)</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Delivery before EP</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >13 (34.2)</td><td align="center" valign="middle" >25 (65.8)</td><td align="center" valign="middle" >0.52 (0.19 - 1.36)</td><td align="center" valign="middle" >0.137</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >16 (50.0)</td><td align="center" valign="middle" >16 (50.0)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >Endo-uterine manipulation</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >12 (42.9)</td><td align="center" valign="middle" >16 (57.1)</td><td align="center" valign="middle" >1.10 (0.41 - 2.90)</td><td align="center" valign="middle" >0.519</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >17 (40.5)</td><td align="center" valign="middle" >25 (59.5)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >History of STI</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >20 (54.1)</td><td align="center" valign="middle" >17 (45.9)</td><td align="center" valign="middle" >3.13 (1.15 - 8.54)</td><td align="center" valign="middle" >0.021</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >9 (27.3)</td><td align="center" valign="middle" >24 (72.7)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >History of tubal obstruction</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >7 (100.0)</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >22 (34.9)</td><td align="center" valign="middle" >41 (65.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SOPK</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >4 (100.0)</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >0.026</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >25 (37.9)</td><td align="center" valign="middle" >41 (62.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >History of pelvic surgery</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Yes</td><td align="center" valign="middle" >5 (50.0)</td><td align="center" valign="middle" >5 (50.0)</td><td align="center" valign="middle" >1.50 (0.39 - 5.74)</td><td align="center" valign="middle" >0.397</td></tr><tr><td align="center" valign="middle" >No</td><td align="center" valign="middle" >24 (40.0)</td><td align="center" valign="middle" >36 (60.0)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MTX protocol</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Single dose</td><td align="center" valign="middle" >13 (44.8)</td><td align="center" valign="middle" >16 (55.2)</td><td align="center" valign="middle" >1.27 (0.48 - 3.32)</td><td align="center" valign="middle" >0.405</td></tr><tr><td align="center" valign="middle" >Multidose</td><td align="center" valign="middle" >16 (39.0)</td><td align="center" valign="middle" >25 (61.0)</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >EP Location</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Ampullary</td><td align="center" valign="middle" >19 (44.2)</td><td align="center" valign="middle" >24 (55.8)</td><td align="center" valign="middle" >1.34 (0.50 - 3.61)</td><td align="center" valign="middle" >0.368</td></tr><tr><td align="center" valign="middle" >Interstitial</td><td align="center" valign="middle" >0 (0.0)</td><td align="center" valign="middle" >2 (100.0)</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >0.340</td></tr><tr><td align="center" valign="middle" >Infundibular</td><td align="center" valign="middle" >4 (30.8)</td><td align="center" valign="middle" >9 (69.2)</td><td align="center" valign="middle" >0.56 (0.15 - 2.06)</td><td align="center" valign="middle" >0.294</td></tr><tr><td align="center" valign="middle" >Isthmic</td><td align="center" valign="middle" >6 (50.0)</td><td align="center" valign="middle" >6 (50.0)</td><td align="center" valign="middle" >1.52 (0.43 - 5.3)</td><td align="center" valign="middle" >0.363</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Independent factors associate with absence of spontaneous conception</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Variables</th><th align="center" valign="middle"  colspan="2"  >Absence of spontaneous conception</th><th align="center" valign="middle"  rowspan="2"  >OR (IC &#224; 95%)</th><th align="center" valign="middle"  rowspan="2"  >Ajusted P</th></tr></thead><tr><td align="center" valign="middle" >N = 29; n (%)</td><td align="center" valign="middle" >N = 41; n (%)</td></tr><tr><td align="center" valign="middle" >History of STI</td><td align="center" valign="middle" >20 (54.1)</td><td align="center" valign="middle" >17 (45.9)</td><td align="center" valign="middle" >2.22 (0.74 - 6.61)</td><td align="center" valign="middle" >0.151</td></tr></tbody></table></table-wrap><p>not conceiving spontaneously after medical management of an EP (p = 0.021), after univariate analysis.</p></sec><sec id="s3_6_2"><title>3.6.2. Multivariate Analysis</title><p>After multivariate analysis using the binary logistic regression method, we were unable to confirm that there was an association between a history of STIs and fertility prognosis (<xref ref-type="table" rid="table8">Table 8</xref>).</p></sec></sec></sec><sec id="s4"><title>4. Discussion</title><p>The aim of our study was to evaluate the prognosis of subsequent spontaneous fertility of patients after medical treatment of tubal ectopic pregnancy in two hospitals in the city of Yaound&#233;. More specifically, we sought to describe the sociodemographic and clinical characteristics of patients who had undergone medical treatment for EP; to describe the different therapeutic protocols; to determine the spontaneous conception rate after medical treatment; and to report the mean time to conception after medical treatment for EP.</p><p>The mean age of our study population was 27.8 &#177; 3.81 years, which is similar to the result found by Kenfack et al. in Cameroon [<xref ref-type="bibr" rid="scirp.130949-ref6">6</xref>] , who found a mean age of 26.46 &#177; 5.42 years. The most affected age group was [21 - 35] years, which is in the same line to what Dohbit et al. found in 2010 in Cameroon [<xref ref-type="bibr" rid="scirp.130949-ref7">7</xref>] . These similarities could be justified by the fact that the majority of our patients were single, had a higher level of education (mostly students) and that this predominant age group corresponds to a period of intense genital activity in women and to increased risky sexual behaviour in our context [<xref ref-type="bibr" rid="scirp.130949-ref8">8</xref>] .</p><p>The past medical history of our patients revealed that 52.9% had a pelvic inflammatory disease and the most frequently germ found was Chlamydia trachomatis (47.1%). On the other hand almost 15% of our study population had already undergone surgery for EP. Assessing risk factors for ectopic pregnancy in a population of Cameroonian women, Assouni et al. found a 13-fold increased risk of developing an ectopic pregnancy in women with PID [<xref ref-type="bibr" rid="scirp.130949-ref9">9</xref>] . Similarly, in a retrospective cohort of 30,450 PID patients and 91,350 controls, Huang et al. found that PID patients had a 2.121-fold (p = 0.003) higher risk of developing an ectopic pregnancy in Taiwan region [<xref ref-type="bibr" rid="scirp.130949-ref10">10</xref>] . All these results are supported by Xia et al. who explored the relationship between chlamydia trachomatis infections and ectopic pregnancy in a recent meta-analysis and systematic review, and found that the association between chlamydia trachomatis infections and the risk of EP showed an odds ratio (OR) of 3.03, with a 95% confidence interval (CI) of 2.37 to 3.89 [<xref ref-type="bibr" rid="scirp.130949-ref11">11</xref>] . Our result is therefore in line with numerous studies that have identified PID as a major risk factor for EP, due to scarring leading to tubal obstruction that interferes with egg capture and migration.</p><p>The median Fernandez score was 11, with a minimum score of 4 and a maximum score of 13, which justified the choice of medical treatment for EP according to the score recommendations; the administration route of methotrexate was intramuscular (IM) in all our patients. This result is similar to that of Am&#233;lie Gervaise et al. [<xref ref-type="bibr" rid="scirp.130949-ref12">12</xref>] in 2004 in France, where the preferred administration route was intramuscular in 51.6% of cases. This is due to the non-invasive and easily achievable nature of IM injection; and the single-dose protocol was used most frequently in 58.6% of cases, which is similar to the results found by Silvia Baggio et al. [<xref ref-type="bibr" rid="scirp.130949-ref2">2</xref>] in 2021, where the single-dose protocol was used in 71.7% of patients with fewer side effects and a similar success rate to the multi-dose protocol [<xref ref-type="bibr" rid="scirp.130949-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref14">14</xref>] . The initial B-HCG level was &lt;3000 in 75.7% of cases and, at D7, this level was less than 1000 IU in 51.4% of cases, with a percentage reduction in B-HCG during the first week of between 40% and 70%.</p><p>After medical treatment of EP with MTX, we observed a spontaneous conception rate of 58.6% with a recurrence rate of EP of 14.6%. Several studies have reported similar results, with post-treatment conception rates ranging from 55% to 80% [<xref ref-type="bibr" rid="scirp.130949-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.130949-ref15">15</xref>] . In trials comparing the spontaneous conception rate after expectant management, medical treatment with MTX and surgery, the spontaneous conception rate after medical treatment with MTX was slightly lower than after surgery, but the recurrence rate of EP was significantly higher in the surgery group. This suggests a better efficacy in terms of intrauterine pregnancy after medical treatment with MTX, certainly due to the non-invasive nature of the procedure and the almost complete absence of the risk of pelvic or intra-tubal adhesions associated with surgery.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The spontaneous fertility rate after medical management of EP was 58.6%, of which 73.2% were term pregnancies and 14.6% were recurrent ectopic pregnancies.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Cyrille, N.N.C., Hilary, T.G., Robert, N.S., Kondo, A.R.N., Gregory, A., Madye, N.D.A. and Isidore, T. (2024) Evaluation of Spontaneous Fertility after Medical Treatment of Tubal Ectopic Pregnancy in Two Hospitals in the City of Yaounde. Open Journal of Obstetrics and Gynecology, 14, 175-185. https://doi.org/10.4236/ojog.2024.141016</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130949-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Orazulike, N.C. and Konje, J.C. (2013) Diagnosis and Management of Ectopic Pregnancy. Women’s Health, 9, 373-385. https://doi.org/10.2217/WHE.13.35</mixed-citation></ref><ref id="scirp.130949-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Baggio, S., Garzon, S., Russo, A., Ianniciello, C.Q., Santi, L,. Laganà, A.S., et al. (2021) Fertility and Reproductive Outcome after Tubal Ectopic Pregnancy: Comparison among Methotrexate, Surgery and Expectant Management. Archives of Gynecology and Obstetrics, 303, 259-268. https://doi.org/10.1007/s00404-020-05749-2</mixed-citation></ref><ref id="scirp.130949-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Akande, V., Turner, C., Horner, P., Horne, A. and Pacey, A. (2010) Impact of Chlamydia trachomatis in the Reproductive Setting: British Fertility Society Guidelines for Practice. Human Fertility, 13, 115-125.  
https://doi.org/10.3109/14647273.2010.513893</mixed-citation></ref><ref id="scirp.130949-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Asgari, Z., Chegini, V., Hosseini, R., Mohajeri, M. and Ansari, I. (2021) Fertility Outcomes Subsequent to Medical and Surgical Treatment for Ectopic Pregnancy: A Retrospective Cohort Study in Iran. International Journal of Reproductive BioMedicine, 19, 881-888. https://doi.org/10.18502/ijrm.v19i10.9820</mixed-citation></ref><ref id="scirp.130949-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kenfack, B., Nguefack-Tsague, G., Ateudjeu, J., Che, G.A. and Mboudou, E.T. (2015) Fertility after Ectopic Pregnancy in a District Hospital in Cameroon. International Journal of Gynecology &amp; Obstetrics, 130, 165-168.  
https://doi.org/10.1016/j.ijgo.2015.02.027</mixed-citation></ref><ref id="scirp.130949-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kenfack, B., Noubom, M., Bongoe, A., Tsatedem, F.A., Ngono, M., Tsague, G.N., et al. (2012) La grossesse extra-utérine dans une région semi-rurale en Afrique: Aspects épidémiologiques, cliniques et thérapeutiques à propos d’une série de 74 cas traités à l’H&amp;#244;pital de District de Sangmelima au Sud-Cameroun. Pan African Medical Journal, 13, 71.</mixed-citation></ref><ref id="scirp.130949-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Dohbit, J.S., Foumane, P., Kapche, M.D., Mboudou, E.T., Doumbe, M. and Doh, A.S. (2010) Grossesse Extra-Uterine a l’hopital regional de bafoussam: Aspects épidémiologiques, cliniques et thérapeutiques. Clinics in Mother and Child Health, 7, 1189-1193. https://www.ajol.info/index.php/cmch/article/view/60568   
https://doi.org/10.4303/cmch/C101977</mixed-citation></ref><ref id="scirp.130949-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Felix, E., Ngo, U.M.E., Kondo, A.N., Fize, S.K.S., Ayissi, G. and Mbu, E.R. (2019) Sexual Risk Behaviour in a Student Population of the University of Yaoundé I, Cameroon. Revue de médecine et de pharmacie, 9, 1050-1056.</mixed-citation></ref><ref id="scirp.130949-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Assouni Mindjah, Y.A., Essiben, F., Foumane, P., Dohbit, J.S. and Mboudou, E.T. (2018) Risk Factors for Ectopic Pregnancy in a Population of Cameroonian Women: A Case-Control Study. PLOS ONE, 13, e0207699.  
https://doi.org/10.1371/journal.pone.0207699</mixed-citation></ref><ref id="scirp.130949-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C.C., Huang, C.C., Lin, S.Y., Chang, C.Y.Y., Lin, W.C., Chung, C.H., et al. (2019) Association of Pelvic Inflammatory Disease (PID) with Ectopic Pregnancy and Preterm Labor in Taiwan Region: A Nationwide Population-Based Retrospective Cohort Study. PLOS ONE, 14, e0219351.  
https://doi.org/10.1371/journal.pone.0219351</mixed-citation></ref><ref id="scirp.130949-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hao, H.J., Feng, L., Dong, L.F., Zhang, W. and Zhao, X.L. (2023) Reproductive Outcomes of Ectopic Pregnancy with Conservative and Surgical Treatment: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 102, e33621.  
https://doi.org/10.1097/MD.0000000000033621</mixed-citation></ref><ref id="scirp.130949-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Gervaise, A., Masson, L., de Tayrac, R., Frydman, R. and Fernandez, H. (2004) Reproductive Outcome after Methotrexate Treatment of Tubal Pregnancies. Fertility and Sterility, 82, 304-308. https://doi.org/10.1016/j.fertnstert.2004.04.023</mixed-citation></ref><ref id="scirp.130949-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Guvendag Guven, E.S., Dilbaz, S., Dilbaz, B., Aykan Yildirim, B., Akdag, D. and Haberal, A. (2010) Comparison of Single and Multiple Dose Methotrexate Therapy for Unruptured Tubal Ectopic Pregnancy: A Prospective Randomized Study. Acta Obstetricia et Gynecologica Scandinavica, 89, 889-895.  
https://doi.org/10.3109/00016349.2010.486825</mixed-citation></ref><ref id="scirp.130949-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yang, C., Cai, J., Geng, Y. and Gao, Y. (2017) Multiple-Dose and Double-Dose versus Single-Dose Administration of Methotrexate for the Treatment of Ectopic Pregnancy: A Systematic Review and Meta-Analysis. Reproductive Biomedicine, 34, 383-391.  
https://doi.org/10.1016/j.rbmo.2017.01.004</mixed-citation></ref><ref id="scirp.130949-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Düz, S.A. (2021) Fertility Outcomes after Medical and Surgical Management of Tubal Ectopic Pregnancy. Acta clinica Croatica, 60, 347-353.  
https://doi.org/10.20471/acc.2021.60.03.02</mixed-citation></ref></ref-list></back></article>